Thermo Fisher Scientific Inc. $TMO Shares Bought by Sax Wealth Advisors LLC

Key Points

• Sax Wealth Advisors LLC increased its holdings in Thermo Fisher Scientific by 152.6%, owning 1,579 shares worth approximately $640,000 as of the latest SEC filing.
• Institutional investors currently own 89.23% of Thermo Fisher's stock, indicating strong institutional interest in the medical research company.
• Thermo Fisher's recent quarterly earnings showed revenue growth of 2.9% year-over-year, with a reported EPS of $5.36, exceeding analysts' expectations.

Sax Wealth Advisors LLC grew its holdings in shares of Thermo Fisher Scientific Inc. (NYSE:TMO - Free Report) by 152.6% in the 2nd quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 1,579 shares of the medical research company's stock after acquiring an additional 954 shares during the period. Sax Wealth Advisors LLC's holdings in Thermo Fisher Scientific were worth $640,000 as of its most recent SEC filing.

Several other large investors also recently modified their holdings of the business. WestEnd Advisors LLC lifted its position in shares of Thermo Fisher Scientific by 28.5% during the second quarter. WestEnd Advisors LLC now owns 85,492 shares of the medical research company's stock worth $34,665,000 after purchasing an additional 18,950 shares during the last quarter. BankPlus Trust Department lifted its position in shares of Thermo Fisher Scientific by 4.6% during the second quarter. BankPlus Trust Department now owns 2,752 shares of the medical research company's stock worth $1,116,000 after purchasing an additional 121 shares during the last quarter. Shell Asset Management Co. lifted its position in shares of Thermo Fisher Scientific by 6.6% during the second quarter. Shell Asset Management Co. now owns 22,472 shares of the medical research company's stock worth $9,111,000 after purchasing an additional 1,390 shares during the last quarter. Slow Capital Inc. lifted its position in shares of Thermo Fisher Scientific by 1.5% during the second quarter. Slow Capital Inc. now owns 7,442 shares of the medical research company's stock worth $3,019,000 after purchasing an additional 112 shares during the last quarter. Finally, KLP Kapitalforvaltning AS lifted its position in shares of Thermo Fisher Scientific by 4.1% during the second quarter. KLP Kapitalforvaltning AS now owns 142,683 shares of the medical research company's stock worth $57,904,000 after purchasing an additional 5,600 shares during the last quarter. 89.23% of the stock is currently owned by institutional investors and hedge funds.

Insiders Place Their Bets

In other Thermo Fisher Scientific news, EVP Gianluca Pettiti sold 400 shares of Thermo Fisher Scientific stock in a transaction that occurred on Friday, July 25th. The shares were sold at an average price of $479.98, for a total value of $191,992.00. Following the transaction, the executive vice president owned 22,367 shares in the company, valued at approximately $10,735,712.66. The trade was a 1.76% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Also, CEO Marc N. Casper sold 10,000 shares of Thermo Fisher Scientific stock in a transaction that occurred on Friday, August 22nd. The stock was sold at an average price of $500.96, for a total transaction of $5,009,600.00. Following the completion of the transaction, the chief executive officer owned 115,174 shares in the company, valued at approximately $57,697,567.04. This trade represents a 7.99% decrease in their position. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 30,066 shares of company stock worth $14,182,963. 0.33% of the stock is owned by insiders.

Thermo Fisher Scientific Price Performance

NYSE TMO opened at $536.21 on Thursday. Thermo Fisher Scientific Inc. has a 12 month low of $385.46 and a 12 month high of $610.97. The company has a debt-to-equity ratio of 0.65, a current ratio of 1.93 and a quick ratio of 1.50. The firm has a market capitalization of $202.48 billion, a PE ratio of 31.01, a P/E/G ratio of 2.93 and a beta of 0.77. The company's 50 day simple moving average is $486.09 and its 200 day simple moving average is $448.21.

Thermo Fisher Scientific (NYSE:TMO - Get Free Report) last posted its quarterly earnings data on Wednesday, July 23rd. The medical research company reported $5.36 EPS for the quarter, beating analysts' consensus estimates of $5.22 by $0.14. Thermo Fisher Scientific had a net margin of 15.24% and a return on equity of 16.82%. The business had revenue of $10.86 billion for the quarter, compared to analyst estimates of $10.68 billion. During the same quarter last year, the business earned $5.37 earnings per share. The business's revenue for the quarter was up 2.9% on a year-over-year basis. Thermo Fisher Scientific has set its Q3 2025 guidance at 5.460-5.510 EPS. FY 2025 guidance at 22.220-22.840 EPS. As a group, equities research analysts forecast that Thermo Fisher Scientific Inc. will post 23.28 EPS for the current fiscal year.

Analysts Set New Price Targets

Several equities analysts have recently commented on the stock. Redburn Partners set a $580.00 price target on shares of Thermo Fisher Scientific in a research report on Wednesday. Barclays raised their target price on shares of Thermo Fisher Scientific from $550.00 to $585.00 and gave the stock an "overweight" rating in a report on Thursday, October 2nd. Weiss Ratings reissued a "hold (c-)" rating on shares of Thermo Fisher Scientific in a report on Saturday, September 27th. Hsbc Global Res cut shares of Thermo Fisher Scientific from a "strong-buy" rating to a "hold" rating in a report on Thursday, July 24th. Finally, UBS Group raised their target price on shares of Thermo Fisher Scientific from $460.00 to $500.00 and gave the stock a "neutral" rating in a report on Thursday, July 24th. Fifteen equities research analysts have rated the stock with a Buy rating and six have assigned a Hold rating to the company's stock. According to data from MarketBeat.com, the stock presently has an average rating of "Moderate Buy" and a consensus price target of $590.60.

Thermo Fisher Scientific Company Profile

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.